Payment overview · 2025
General Payments
$4,270.05
205 reported records · 31 companies
Healthcare provider profile · identity verified
Mike Liu, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FORT WORTH, TX · NPI 1225489255
Verified facts
What the public records show
CMS Open Payments records show Mike Liu, DO received $4,270.05 in general payments during 2025 across 205 reported records.
ABBVIE INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xcopri.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rytary by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $806.41 | 18.9% | 43 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $362.56 | 8.5% | 19 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $347.36 | 8.1% | 18 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$340.01 | 8.0% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $298.93 | 7.0% | 14 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $262.79 | 6.2% | 9 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $232.01 | 5.4% | 8 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $196.85 | 4.6% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $175.46 | 4.1% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $152.10 | 3.6% | 12 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $147.10 | 3.4% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.98 | 3.4% | 10 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $103.24 | 2.4% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $92.24 | 2.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $74.77 | 1.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.46 | 1.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.73 | 1.6% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $64.16 | 1.5% | 3 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.26 | 1.5% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $34.96 | 0.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.22 | 0.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.99 | 0.5% | 1 | 2025 |
| OWP Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.77 | 0.5% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $22.49 | 0.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $22.41 | 0.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.41 | 0.5% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.91 | 0.5% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $18.79 | 0.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.28 | 0.4% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $15.87 | 0.4% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $13.53 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,115.96 | 202 |
| Education | $132.00 | 2 |
| Honoraria | $22.09 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $522.60 | 32 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $502.48 | 37 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $436.90 | 18 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $347.36 | 18 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $232.01 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $199.32 | 13 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $196.85 | 4 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $184.09 | 5 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $175.46 | 6 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $158.86 | 8 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $147.10 | 8 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $128.21 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $114.69 | 8 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $103.24 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $99.61 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $89.70 | 7 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $84.01 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $74.77 | 4 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $71.00 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $67.73 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $64.16 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $62.40 | 5 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $62.26 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.35 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| Subvenite Normalized: subvenite |
Drug | OWP Pharmaceuticals, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| REYVOW Normalized: reyvow |
Drug | Lilly USA, LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| OMNIA Normalized: omnia |
Device | Globus Medical, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 455 | 162 |
| Donepezil Hcl | Donepezil Hcl | 312 | 109 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 273 | 108 |
| Gabapentin | Gabapentin | 192 | 98 |
| Levetiracetam | Levetiracetam | 173 | 44 |
| Rivastigmine | Rivastigmine Tartrate | 111 | 35 |
| Zonisamide | Zonisamide | 91 | 31 |
| Lamotrigine | Lamotrigine | 89 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 36 |
| Topiramate | Topiramate | 78 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 27 |
| Mirtazapine | Mirtazapine | 63 | 27 |
| Primidone | Primidone | 61 | 29 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Pregabalin | Pregabalin | 49 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 18 |
| Sertraline Hcl | Sertraline Hcl | 41 | 23 |
| Aptiom | Eslicarbazepine Acetate | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | 16 |
| Xcopri | Cenobamate | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | 14 |
| Lacosamide | Lacosamide | 27 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | 12 |
| Rytary | Carbidopa/Levodopa | 15 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Teriflunomide | Teriflunomide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,270.05 · 205 records | ABBVIE INC. | AMYVID, BRIUMVI, Bafiertam, CREXONT, ELYXYB - CELECOXIB, EMGALITY, EPIDIOLEX, GOMEKLI, Gamunex-C, Gocovri, KESIMPTA, KISUNLA, LEQEMBI, Motpoly XR, NURTEC ODT, OMNIA, Ocrevus Zunovo, PANZYGA, QULIPTA, Qelbree, REXULTI, REYVOW, Rystiggo, SKYCLARYS, Senza, Subvenite, Symbravo, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, XCOPRI, ZAVZPRET, ZEMBRACE SYMTOUCH | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xcopri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error